Caisse DE Depot ET Placement DU Quebec Has $105.95 Million Stock Holdings in Stryker Corporation $SYK

Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 13.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 284,613 shares of the medical technology company’s stock after buying an additional 33,453 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned 0.07% of Stryker worth $105,947,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Elefante Mark B acquired a new position in shares of Stryker during the fourth quarter valued at about $337,000. Mogy Joel R Investment Counsel Inc. grew its holdings in shares of Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company’s stock valued at $36,561,000 after buying an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. grew its holdings in shares of Stryker by 1.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company’s stock valued at $65,096,000 after buying an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new position in shares of Stryker during the first quarter valued at about $1,840,000. Finally, Mar Vista Investment Partners LLC grew its holdings in shares of Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after buying an additional 8,353 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.90% of the stock is currently owned by company insiders.

Stryker Stock Performance

Shares of SYK stock opened at $393.8040 on Monday. The firm has a market cap of $150.55 billion, a price-to-earnings ratio of 52.16, a P/E/G ratio of 2.86 and a beta of 0.91. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The firm’s 50-day simple moving average is $387.51 and its two-hundred day simple moving average is $379.25.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is 44.50%.

Analysts Set New Price Targets

Several research firms recently weighed in on SYK. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Friday, July 18th. Truist Financial set a $415.00 price target on shares of Stryker and gave the stock a “hold” rating in a report on Monday, August 4th. Wells Fargo & Company boosted their price target on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. JMP Securities restated a “market perform” rating on shares of Stryker in a report on Monday, May 5th. Finally, Needham & Company LLC boosted their price target on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $430.10.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.